CBD products could be prescribed to British patients from as early as next month after the UK government announced plans to lift restrictions on the medical use of cannabis.

The change in policy follows recommendations from the Advisory Council on the Misuse of Drugs (ACMD) and the UK’s Chief Medical Adviser.

The new law will not limit the types of condition that can be considered for treatment with cannabis and cannabis-derivative products. Doctors will no longer need to seek approval from an expert panel in order for patients to access the medicines.

While CBD is not explicitly listed in the legislation, it is understood that it would fall under the umbrella of cannabis-derived medicines.

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization